🇺🇸 FDA
Patent

US 11884718

Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

granted A61KA61K2039/505A61K2039/5252

Quick answer

US patent 11884718 (Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination) held by The Government of the United States, as represented by the Secretary of the Army expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States, as represented by the Secretary of the Army
Grant date
Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/5252, A61K39/12, A61P